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Systematic reviewBackground: Rotavirus (RV) infection is the leading cause of diarrhoea-associated morbidity and mortal-
ity globally among children under 5 years of age. RV vaccination is available, but has not been imple-
mented in many national immunisation plans, especially in highly developed countries. This
systematic review aimed to estimate the prevalence and incidence of health care use for RV gastroenteri-
tis (RVGE) among children aged under 5 years in highly developed countries without routine RV vaccina-
tion.
Methods: We searched MEDLINE and Embase databases from January 1st 2000 to December 17th 2018 for
publications reporting on incidence or prevalence of RVGE-related health care use in children below
5 years of age: primary care and emergency department (ED) visits, hospitalisations, nosocomial infec-
tions and deaths. We included only studies with laboratory-confirmed RV infection, undertaken in highly
developed countries with no RV routine vaccination plans. We used random effects meta-analysis to gen-
erate summary estimates with 95% confidence intervals (CI) and prediction intervals.
Results: We screened 4033 abstracts and included 74 studies from 21 countries. Average incidence rates
of RVGE per 100 000 person-years were: 2484 (95% CI 697-5366) primary care visits, 1890 (1597-2207)
ED visits, 500 (422-584) hospitalisations, 34 (20–51) nosocomial infections and 0.04 (0.02–0.07) deaths.
Average proportions of cases of acute gastroenteritis caused by RV were: 21% (95% CI 16-26%) for primary
care visits; 32% (25-38%) for ED visits; 41% (36-47%) for hospitalisations, 29% (25–34%) for nosocomial
infections and 12% (8–18%) for deaths. Results varied widely between and within countries, and hetero-
geneity was high (I2 > 90%) in most models.
Conclusion: RV in children under 5 years causes many healthcare visits and hospitalisations, with low
mortality, in highly developed countries without routine RV vaccination. The health care use estimates
for RVGE obtained by this study can be used to model RV vaccine cost-effectiveness in highly developed
countries.
`2021 The Author(s). Published by Elsevier Ltd. This is an openaccess article under theCCBY license (http://
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Rotavirus (RV) infection is the leading cause of diarrhoea-
associated morbidity and mortality globally among children under
5 years of age [1]. RV-associated deaths are rare in high-income
countries, but RV was estimated to account for 4.9 million episodes
of diarrhoea among children younger than 5 years in Western Eur-
ope in 2016 [1]. The proportion of hospitalisations for acute gas-
troenteritis in children under 5 years caused by RV varies
worldwide but has been reported to be 30–40% in both high- and
low-income countries [2]. RV gastroenteritis (RVGE) therefore still
poses a considerable burden on health care resources, although it is
a vaccine-preventable disease.
Oral RV vaccines have been available since 2006 and have
proven clinical efficacy against severe RVGE in different regions
of the world, as summarised in a Cochrane review of ran-
domised controlled trials in 2019 [3]. The World Health Organi-
zation (WHO) recommended the inclusion of RV vaccine in all
national immunisation programmes in 2009, especially for
countries at high risk of severe disease and mortality [4]. In
Europe, however, only one third of countries had introduced
RV vaccination in their national vaccination programmes in
2016 [5]. The low mortality and relatively high costs of the
RV vaccine have led public health authorities in high-income
countries to question the cost-effectiveness of the vaccine
[6,7]. However, the burden on healthcare of RV-related disease
includes the morbidity that leads to primary care consultations,
emergency care, hospitalisations and nosocomial infections, as
well as mortality (Fig. 1).
Previous systematic reviews have described the burden of RV-
related health care use [2,8–14]. Most included studies from low
and middle-income countries and did not include RV-related dis-
ease at all health care levels, from primary care visits to mortality
[2,8–11,13]. The most recent review of RV health care use, includ-
ing studies published up to 2016, also includes countries that have
introduced routine RV vaccination [15]. To assess the cost-
effectiveness of RV vaccines in high-income countries, we need
estimates of RV-related health care use estimates that include all
levels of care. We conducted a systematic review and meta-
analysis to estimate the incidence and prevalence of primary and
emergency care visits, hospitalisations, nosocomial infections and
deaths for RVGE among children under 5 years in highly developed
countries that had not introduced routine RV vaccination by 2018.2
2. Methods
The protocol for this systematic review has been registered in
the PROSPERO repository (CRD42019118069). We used the Pre-
ferred Reporting Items for Systematic Reviews and meta-
Analyses statement (PRISMA, research checklist online) [16] to
report our findings.2.1. Eligibility criteria
We searched for scientific manuscripts reporting on health care
use for RVGE in children under 5 years old in highly developed
countries, before routine RV vaccination introduction. To obtain
accurate estimates, we included only studies that included chil-
dren seen or hospitalised for acute gastroenteritis and that used
specific and reliable tests to diagnose RVGE and specified age
ranges. We defined highly developed countries as those with a
good healthcare system (WHO mortality strata A: low adult mor-
tality, very low child mortality [17]), a democratic government
and a high-income economy (Organization for Economic Coopera-
tion and Development (OECD) member [18]). The list of eligible
countries is shown in Supplementary Table 1. To reduce the risk
of biases from studies with small sample sizes, misclassification
of diagnosis and limited study period, we defined exclusion criteria
based on sample size, year of publication and study duration. The
detailed inclusion and exclusion criteria are described in the Sup-
plementary Material (p. 10).2.2. Information sources and search strategy
We searched the Embase and MEDLINE databases on December
17, 2018. Our search strings included medical subject headings
(MeSH) or thesaurus terms and free text key words pertaining to
(1) rotavirus, (2) disease outbreak, surveillance or epidemiology,
(3) names of major geographic regions or cities in eligible countries
and (4) infancy and childhood. The complete search strings are pre-
sented in the Supplementary Material (p. 5). We used an auto-
mated procedure to eliminate duplicates and generated an
EndNoteX8 (Clarivate Analytics, Philadelphia, Pennsylvania, United
States of America, USA) library to screen retrieved records.
A) Asymptomac infecons
B) Mild infecons (treated at home) 
C) Primary care visits 












Fig. 1. Contributions to rotavirus burden of health care use. Levels C through F were estimated in our study.
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We screened titles and abstracts to assess eligibility using an
accelerated process (screening by one reviewer, followed by confir-
mation of records for exclusion by a second reviewer) [19]. Two
reviewers then independently screened the full-texts of potentially
eligible studies in duplicate. Disagreements were settled by con-
sensus or by discussion with a third researcher.
2.4. Data extraction
We extracted the data from all eligible publications into a pre-
piloted standard data extraction form in a secure online database
(Research Electronic Data Capture, REDCap, Vanderbilt University,
Tennessee, USA). Data extraction was done by one reviewer and
checked by a second reviewer (e.g. missing details or to confirm
important data). We extracted information on the publication,
study characteristics and the number and characteristics of the
participants, the authors’ definitions of the outcome measure,
numerical results and the specific laboratory procedure for identi-
fication of causal pathogens. A detailed list of items extracted is
described in the Supplementary Material (p. 10).
2.5. Risk of bias assessment
We assessed the risk of bias in individual studies by adapting
the tool proposed by Hoy et al. [20] to asses population based
prevalence studies. The checklist contains 10 items classified as:
Yes (low risk) or No (high risk). Questions 1–4 assess external
validity and 5–10 internal validity. Further details can be found
in the Supplementary Material (p. 11).
2.6. Synthesis of results and analysis
For each study and outcome, we used the number of positive RV
stools samples and the person-years of the population at risk to
calculate incidence rates, and the number of cases of acute gas-
troenteritis and the number of RV positive stool samples to calcu-
late pooled proportions. When the number of RVGE cases were not
reported, we calculated it based on person-years and incidence
rates. Similarly, if the number of person-years was not reported,
we calculated it based on the incidence rate and 95% confidence
interval. For proportions, if only the numerator (RV positive stool
samples) or the denominator (number of all cases of acute gas-3
troenteritis) were reported, we used the reported proportion of
RVGE to calculate the other number. For nosocomial infections,
we only included those reported to occur during hospitalisation.
We performed random effects meta-analysis to calculate sum-
mary estimates of average incidence rates or proportions (with
95% CI). We used the Freeman-Tukey Double arcsine transforma-
tion to calculate the overall incidence rate or proportion [21]. We
examined heterogeneity graphically, using forest plots, statistically
by calculating the I2 and Tau-squared statistics [22], and in sub-
group analyses at the country level. We calculated the prediction
interval to indicate the range of the predicted proportion or inci-
dence rate in a new study conditional on the previous studies
[22,23]. However, if the heterogeneity between studies was so
large as to render the prediction interval uninformative, the pre-
diction interval was not plotted along with the forest plots. We
did not test the included studies for potential risk of publication
bias because the relevance for studies of prevalence or incidence
is uncertain. We used the R language for statistical computing for
all analysis, using the metaprop and metarate functions of the
package ‘meta’ [24] and package ‘epitools’ [25].
We performed three sensitivity analyses to explore possible
causes of heterogeneity. First, we assessed incidence rates and pro-
portions in studies that included only children under 2 years of age,
as severe RVGE affects particularly children of this age range. For
this, we selected studies that included children aged between 0
and 24 months. In a second sensitivity analysis we assessed if
the risk of bias in the studies affected the pooled estimates for chil-
dren under 5 years old. For this analysis, we selected studies with a
low risk of bias score for selection and non-response bias, i.e. items
3 and 4 on the Hoy et al. risk of bias tool [20]. In the third sensitiv-
ity analysis we assessed if studies that tested the stools only for RV
and not for multiple pathogens, might be attributing RV as the
cause for the acute gastroenteritis, when the child is only excreting
RV, and the symptoms are caused by another pathogen. For this,
we included only studies that tested stool samples also for other
gastrointestinal pathogens apart from RV.3. Results
Our electronic search identified 4033 records after removing
duplicates, of which we selected 1336 based on screening of titles
and abstracts. Of these, we included 77 full-text manuscripts
reporting on 74 studies in the systematic review [26–100]
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tries in North America, Europe, Asia and Oceania.
We describe results for different levels of health care use: pri-
mary care, emergency care, hospitalisations, nosocomial infections
and deaths. For each level of health care use, we present summary
estimates of incidence rates and proportions of acute gastroenteri-
tis caused by RV infection in children under 5 years of age
(Table 1).3.1. Primary care visits
The summary incidence rate for primary care visits, estimated
from 3 studies was 2484 (95%CI: 697–5366) per 100 000 person-
years (I2: 99%) (Supplementary Figure 1). The proportion of pri-
mary care visits for acute gastroenteritis caused by RV infection
was 21% (95% CI: 16–26%; prediction interval: 5–44%; I2: 98%) esti-
mated from 14 studies from 9 countries that ranged between 9 and
45% (Fig. 3).Fig. 2. Rotavirus burden of health care u
4
3.2. Emergency care visits
The incidence rate of RVGE emergency care visits in one study
was 1890 per 100 000 children per year (95% CI: 1597–2207)
[82]. The estimated proportion of emergency care visits for acute
gastroenteritis caused by RV infection was 32% (95% CI: 25–38%;
prediction interval: 6–65%; I2: 98%), based on 19 studies from 11
countries (Fig. 4).3.3. Hospitalisations
The summary incidence rate of RVGE hospitalisations was 500
(95%CI: 422–584; prediction interval 221–892; I2: 100%) per 100
000 children per year, based on 13 studies from 9 countries
(Fig. 5). An estimated 41% of hospitalisations for acute gastroen-
teritis were caused by RV infection (95% CI: 36–47%; prediction
interval: 9–79%; I2: 100%) based on 45 studies from 16 countries
(Fig. 6). Summary estimates by country are in Supplementary
Figure 2.se: flow diagram of study selection.
Table 1
Summary table with summary estimates of health care use for rotavirus gastroenteritis in children in highly developed countries with no routine rotavirus vaccination
programmes.






Under 5 years, low risk of
bias*




Proportion (95% CI) 21% (16–26%), 14 24% (14–35%), 2 17% (10–26%), 7 16% (7–28%), 4






– 1036 (814–1285), 1
Emergency care
visits
Proportion (95% CI) 32% (25–38%), 19 34% (9–66%), 2 29% (20–39%), 11 22% (18–26%), 7







Hospitalisa-tions Proportion (95% CI) 41% (36–47%), 45 50% (32–68%), 8 40% (32–47%), 30 38% (31–44%), 16






544 (470–623), 10 333 (41–905), 2
Nosocomial
infections
Proportion (95% CI) 29% (25–34%), 3 53% (46–60%), 3 29% (25–34%), 3 30% (26–35), 2
Incidence per 100 000 person-years
(95% CI)
34 (20–51), 3 95 (90–100), 1 43 (36–50), 2 26 (20–33), 1
Incidence per 1000 hospital-days
(95% CI)
0.63 (41–90), 3 7.09 (1–17), 4 0.61 (0.33–0.98), 2 0.79 (0.68–0.91), 1
Incidence per 1000 hospitalisations
(95% CI)
1.5 (1–2.1), 1 18 (3–46), 3 – –
Mortality Proportion (95% CI) 12% (8–18%), 1 – – –




– 0.04 (0.02–0.07), 2 –
Rate per 100 000 hospitalisations
(95% CI)
129 (81–187), 1 – – –
* Summary estimates including only studies with low risk of bias score for selection and non-response bias, i.e. items 3 and 4 on the Hoy et al. risk of bias tool.
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The summary incidence rate of RVGE nosocomial infections was
34 (95% CI: 20–51) per 100 000 children under 5 years old per year,
with high heterogeneity (I2: 91%, 3 studies) (Supplementary Fig-
ure 3).The incidence rate of RVGE nosocomial infections per 1000
hospital-days reported by 3 studies [31,55,79], was 0.63 cases
(95% CI: 0.41–0.90; prediction interval: 0–7.3; I2: 91%) per 1000
hospital-days (Supplementary Figure 4). One study reported the
incidence proportion of RVGE nosocomial infections per 1000 hos-
pitalisations as 1.5 (95% CI: 0.96–2.15) [91]. The proportion of
nosocomial infections of acute gastroenteritis caused by RV in chil-
dren under 5 years old hospitalised for reasons other than acute
gastroenteritis was 29% (95% CI: 25–34%; prediction interval: 2–
72%; I2: 31%), as estimated from 3 studies (Supplementary
Figure 5).3.5. Mortality
The summary mortality rate for RVGE in children under 5 was
0.04 deaths (95% CI: 0.02–0.07; I2: 0%) per 100 000 person-years
[35,93], as reported in 2 studies from Germany (Supplementary
Figure 6). The proportion of deaths for acute gastroenteritis caused
by RV was reported by one study from the UK as 12% (95% CI: 8–
18%) [88]. The same study also reported mortality for RVGE as
129 (95% CI 81–187) deaths per 100 000 hospitalisations in chil-
dren under 5 years.3.6. Risk of bias
One fifth of the studies (17) met all 10 items; 23 (31%) fulfilled
all the items for external validity and 50 (68%) all for internal valid-
ity items. When assessing external validity (Supplementary Fig-
ure 7), 41 (55%) studies had a study population that was a good
representation of the national population; 74% of studies tested
all children with acute gastroenteritis seen during the study period
in the study population, or tested a random sample of children for
RV; 73% of studies had a low risk of non-response bias. Internal5
validity: 58 (78%) studies used the same method to test all the
stool samples for RV.
3.7. Sensitivity analyses
Our first sensitivity analysis selected only studies that included
children 0–24 months old (Table 1 & Supplementary Figure 8–16).
In this population, the incidence rates of RVGE were higher for pri-
mary care visits, hospitalisations and nosocomial infections, but
not for emergency care visits. No study reported mortality in chil-
dren under 2 years of age. The summary estimated proportions of
primary and emergency care visits for gastroenteritis caused by RV
were slightly higher, whereas for hospitalisations it reached 50%
(compared to 41% in under-5 s) and for nosocomial infections
53% (compared to 29% in under-5 s). The second sensitivity analy-
sis included only studies with low risk of bias (Table 1 & Supple-
mentary Figures 17–23). Overall, the summary incidence rate and
proportion of the five different health care outcomes changed little
when we excluded studies with lower external validity. The third
sensitivity analysis included only studies that looked for other
pathogens in the stool samples (29 of 74). Very few studies report-
ing on incidence of RVGE tested for multiple pathogens, and those
that did reported a lower incidence of primary care visits and hos-
pitalisations than all studies in under-5 s (1036 vs 2484 and 333 vs
500 per 100 000 per year, respectively) (Table 1 & Supplementary
Figure 24–28). The summary estimated proportions of primary
care and emergency visits caused by RV were lower compared to
the main analyses (16% vs 21%, and 22% vs 32%), while that of hos-
pitalisations was similar. Results for nosocomial infections were
similar and none of the studies reporting on mortality tested for
multiple pathogens.
4. Discussion
This systematic review and meta-analysis of RVGE in children
aged under 5 years found that, in highly developed countries with
no RV routine vaccination, every year an average of 500 children
are hospitalised per 100 000 children. Emergency care visits and
primary care visits occurred 4 to 5 times more often than
Fig. 3. Proportion of primary care visits for RVGE among all visits for acute gastroenteritis of children aged 0–5 years (forest plot). RVGE: Rotavirus gastroenteritis; RV+: stools
samples that tested positive for rotavirus; AGE: acute gastroenteritis; CI: Confidence Interval.
C. Ardura-Garcia, C. Kreis, M. Rakic et al. Vaccine xxx (xxxx) xxxhospitalisations. Mortality for RVGE was very low (0.04 deaths per
100 000 person-years; 95% CI: 0.02–0.07). The proportion of acute
gastroenteritis caused by RV was highest for hospitalisations (40%)
and lowest for primary care visits (21%). For nosocomial acute gas-6
troenteritis, an average of 29% was caused by RV. In children aged
under 2 years, the incidence rates of all outcomes were higher than
in children under 5 years old, while the proportions of RVGE
among all acute gastroenteritis were similar. There were large
Fig. 4. Proportion of emergency department consultations for RVGE among all
consultations for acute gastroenteritis of children aged 0–5 years (forest plot).
RVGE: Rotavirus gastroenteritis; RV+: stools samples that tested positive for
rotavirus; AGE: acute gastroenteritis; CI: Confidence Interval.
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high (>90%) in most models.4.1. Strengths and limitations
This systematic review summarised incidence rates and propor-
tions of RVGE disease across all levels of health care use, from pri-
mary care to hospitalisations, including nosocomial infections and
mortality (Fig. 1). This gives a complete picture of the burden of
RVGE in highly developed countries with no routine RV vaccination
programmes. Our inclusion criteria attempted to reduce small
study and measurement biases. We also attempted to identify
causes of heterogeneity, such as age, risk of bias and testing solely
for RV, in sensitivity analyses.7
This review has also limitations. We found high heterogeneity,
both between and within countries. This may be due to differences
in health care systems and climate, so the average summary esti-
mates may not be applicable to all settings. Second, some of the
included studies had a high risk of bias, especially concerning
external validity. However, the summary estimates did not vary
greatly when excluding these studies. Finally, the proportion of
children that had received RV vaccination may have varied
between studies. We excluded studies undertaken after RV vaccine
introduction in national immunisation programmes, but some par-
ents might still have opted to vaccinate their children and pay pri-
vately. We extracted these data from the studies when available,
but it was rarely reported.
4.2. Findings in relation to other studies
For every hospitalisation for RVGE, we estimated an average of
4 emergency care visits and 5 primary care visits. The ratio
between primary care visits and hospitalisations was similar for
children aged under 2. A 2017 European Centre for Disease Preven-
tion and Control (ECDC) report on RV burden in the European
Union also found that there are 2–4 times more visits to the emer-
gency department or other outpatient facilities caused by RVGE
than hospitalisations [14]. However, the proportion of acute gas-
troenteritis caused by RV were half as high for primary care than
for hospitalisations (21% vs 40%). Indeed, RV may lead to more sev-
ere disease with a higher degree of dehydration than other patho-
gens. One previous meta-analysis of studies from China reported
on RVGE burden estimates for different levels of health care. They
found that 33% of outpatient visits for acute gastroenteritis were
caused by RV, and 43% of hospitalisations, similar to our findings
[12].
The higher incidence of RVGE in children under 2 years of age,
especially severe RVGE requiring hospitalisations, has been
reported [11] and is explained by the higher risk of dehydration
in infants. This could account for part of the variation in incidence
and proportions found between studies depending on the age dis-
tribution, which was not reported by all studies.
Hospitalisations for RVGE have been studied worldwide. Two
reviews including high and low-income countries found hospitali-
sation rates for RVGE similar to our study. The ECDC report of 49
studies from the European Union and the European Economic Area,
reported that the hospitalisation incidence rates ranged from 100
to 1190 per 100 000 person years (most of which were between
300 and 600) and the proportion of all acute gastroenteritis hospi-
talisations ranged between 26 and 69% [14], comparable to our
findings. A worldwide review including 242 studies found also a
similar overall proportion of RV-attributable hospitalisations for
acute gastroenteritis in children aged under 5 (38%; 95% CI: 36–
40%) [11]. However, this proportion was lower in studies that
tested for multiple pathogens rather than for RV alone (20% in
studies with 5–13 pathogens vs 39% in single-pathogen studies,
p < 0.0001) [11]. This was not the case in our study for the propor-
tion of hospitalisations, though we also found a lower incidence of
hospitalisations for RVGE in the two studies that tested for multi-
ple pathogens. Worldwide reviews found that the incidence of RV
hospitalisations does not vary much with the level of economic
development (median RV admissions per 1000 children under
5 years per year: 2.0 vs 1.9 in low- and high-income regions,
respectively) [13].
4.3. Implications for health care and future research
The results from this meta-analysis can be used to model the
cost-effectiveness of RV vaccine introduction into national immu-
nisation plans in highly developed countries. Economic evaluations
Fig. 5. Incidence rate of hospitalisations for RVGE of children aged 0–5 years per 100,000 person-years (forest plot). RVGE: Rotavirus gastroenteritis; RV+: stools samples that
tested positive for rotavirus; PY: person-years; CI: Confidence Interval.
C. Ardura-Garcia, C. Kreis, M. Rakic et al. Vaccine xxx (xxxx) xxxwill provide useful information for public health authorities when
deciding upon immunisation strategies for RV. We observed a wide
variation of estimates of RVGE health care use between and within
countries in our review, presumably due to differences in health
care systems, climate and prevalence of other gastrointestinal8
pathogens, but also to differences in study designs (use of hospital
records vs cohort studies with invited participants), specific loca-
tions (multicentre vs single centre studies) and laboratory methods
used (testing for multiple pathogens vs only RV). This has resulted
in the high heterogeneity observed in our pooled models.
Fig. 6. Proportion of hospitalisations for RVGE among all hospitalisations for acute gastroenteritis of children aged 0–5 years (forest plot without country estimates). RVGE:
Rotavirus gastroenteritis; RV+: stools samples that tested positive for rotavirus; AGE: acute gastroenteritis; CI: Confidence Interval.
C. Ardura-Garcia, C. Kreis, M. Rakic et al. Vaccine xxx (xxxx) xxxResearchers assessing RV-related health care in future could obtain
more robust results by using standardised prospective methods
across different countries.5. Conclusion
RV causes a considerable number of health care visits and hos-
pitalisations for gastroenteritis in highly developed countries with-
out routine RV vaccination. RV was one of the main pathogens of9
severe gastroenteritis requiring hospitalisation in children under
5 years. Even though RVGE mortality is low in highly developed
countries, this vaccine-preventable disease poses a considerable
burden on health care systems.Authors contributions
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